Moderna (MRNA) Leases: 2018-2025
Historic Leases for Moderna (MRNA) over the last 6 years, with Sep 2025 value amounting to $738.0 million.
- Moderna's Leases fell 5.87% to $738.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $738.0 million, marking a year-over-year decrease of 5.87%. This contributed to the annual value of $759.0 million for FY2024, which is 6.45% up from last year.
- Latest data reveals that Moderna reported Leases of $738.0 million as of Q3 2025, which was down 1.60% from $750.0 million recorded in Q2 2025.
- Over the past 5 years, Moderna's Leases peaked at $1.2 billion during Q3 2022, and registered a low of $99.0 million during Q1 2021.
- Its 3-year average for Leases is $803.8 million, with a median of $759.0 million in 2024.
- Per our database at Business Quant, Moderna's Leases soared by 638.89% in 2021 and then crashed by 38.00% in 2023.
- Over the past 5 years, Moderna's Leases (Quarterly) stood at $665.0 million in 2021, then skyrocketed by 72.93% to $1.1 billion in 2022, then tumbled by 38.00% to $713.0 million in 2023, then rose by 6.45% to $759.0 million in 2024, then decreased by 5.87% to $738.0 million in 2025.
- Its Leases was $738.0 million in Q3 2025, compared to $750.0 million in Q2 2025 and $752.0 million in Q1 2025.